ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ

1. A.J.Camm, P.Kirchhof, G.Y.Lip et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // Eur Heart J. 2010; 31(19): 2369-429.

2. A.J.Camm, G.Y.Lip, R.De Caterina et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov; 33(21): 2719-47.

3. В.А.Сулимов, С.П.Голицын, Е.П.Панченко с соавт. Диагностика и лечение фибрилляции предсердий (Рекомендации РКО, ВНОА, АССХ). В кн: Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантированных антиаритмических устройств. Изд. «МАКС Пресс», Москва, 2013, с. 367-595.

4. H.Heidbuchel, P.Verhamme, M.Alings et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 15, 625-651 doi: 10.1093/eu-ropace/eut083.

5. G.Y.Lip, S.Windecker, K.Huber et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014 Dec 1; 35(45): 3155-79.

6. S.Windecker, P.Kolh, F.Alfonso et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. doi: 10.1093/eurheartj/ehu278.

7. Ю.В.Шубик. Антитромботическая терапия при фибрилляции предсердий. Вестник аритмологии, 2014, Том 75, с.50-75.

8. Ю.В.Шубик. К вопросу об антикоагулянтной терапии при фибрилляции предсердий. Вестник аритмологии, 2014, Том 78, с.71-72.

9. H.Heidbuchel, P.Verhamme, M.Alings et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace doi: 10.1093/ europace/euv309.

10. M.Roffi, C.Patrono, J.P.Collet et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14; 37(3): 267-315.

11. A.J.Camm, P.Amarenco, S.Haas et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016 Apr 7; 37(14): 1145-53.

12. M.R.Patel, K.W.Mahaffey, J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 15; 365(11): 981-92.

13. R.Cappato, F.E.Marchlinski, S.H.Hohnloser et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015 Jul 21; 36(28): 1805-11. doi: 10.1093/eurheartj/ehv177. Epub 2015 May 14.